Latest revenue
$179.1M
as of 2026-03-31
Latest net income
$169.7M
as of 2026-03-31
Net margin
94.7%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ABUS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $838.5M
- Enterprise value
- $814.8M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.22×
- Dividend yield
- 0.0%
- 52-wk high
- $5.10
- 52-wk low
- $3.04
- Beta
- —
- Shares out
- 197.5M
5-year trend
What this company does
Item 1. Business Overview Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). We continue to protect and defend our intellectual property, which is the subject of our ongoing lawsuit against Pfizer Inc. and BioNTech SE (collectively, Pfizer/BioNTech) for their use of our patented lipid nanoparticle (LNP) technology in their COVID-19…
AI summary unavailable — showing raw filing excerpt
Generated from ABUS's filing dated 2026-03-23
Key risks
Item 1A. Risk Factors Our business is subject to substantial risks and uncertainties. The occurrence of any of the following risks and uncertainties, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations or prospects. In these circumstances, the market price of our common shares could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Risks and uncertainties of general applicability and additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our…
AI summary unavailable — showing raw filing excerpt
Generated from ABUS's filing dated 2026-03-23
Profitability
Operating margin
-271.0%
76.6%Net margin
-237.9%
77.6%Return on equity
-43.7%
39.1%Return on assets
-35.4%
33.3%Leverage
Debt / equity
0.24×
33.2%Debt / assets
19.1%
26.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $179.1M | +10054.5% | $169.7M | +791.9% | 94.7% |
Q4 2025 2025-12-31 | $1.1M | -47.1% | $-3.8M | +70.0% | -357.4% |
Q3 2025 2025-09-30 | $529.0K | -60.5% | $-7.7M | +60.7% | -1463.5% |
Q2 2025 2025-06-30 | $10.7M | +522.2% | $2.5M | +112.7% | 23.5% |
Q1 2025 2025-03-31 | $1.8M | +15.1% | $-24.5M | -37.2% | -1390.4% |
Q4 2024 2024-12-31 | $2.0M | — | $-12.5M | — | -630.4% |
Q3 2024 2024-09-30 | $1.3M | -71.3% | $-19.7M | +1.9% | -1472.5% |
Q2 2024 2024-06-30 | $1.7M | -62.9% | $-19.8M | -15.8% | -1146.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ABUS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ABUS
Institutional value
$156.7M
Total shares held
34.9M
Distinct holders
91
-81 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13.0M | $58.4M | -85.9K (-0.7%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.7M | $30.1M | — | New |
| 3 | Legal & General Group Plc | 2.4M | $10.8M | +2.3M (+1856.1%) | Added |
| 4 | Jefferies Financial Group Inc. | 1.9M | $8.5M | — | New |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.4M | $6.3M | — | New |
| 6 | VANGUARD FIDUCIARY TRUST CO | 1.1M | $4.8M | — | New |
| 7 | CITIGROUP INC | 898.4K | $4.0M | +287.3K (+47.0%) | Added |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 838.2K | $3.8M | -52.7K (-5.9%) | Trimmed |
| 9 | BANK OF MONTREAL /CAN/ | 782.8K | $3.5M | +16.1K (+2.1%) | Added |
| 10 | Western Standard LLC | 521.6K | $2.3M | +13.7K (+2.7%) | Added |
| 11 | Freestone Capital Holdings, LLC | 442.5K | $2.0M | +0 (+0.0%) | No change |
| 12 | KENNEDY CAPITAL MANAGEMENT LLC | 393.1K | $1.8M | -112.0K (-22.2%) | Trimmed |
| 13 | Bank of New York Mellon Corp | 379.4K | $1.7M | -8.5K (-2.2%) | Trimmed |
| 14 | UBS Group AG | 364.5K | $1.6M | +217.2K (+147.4%) | Added |
| 15 | Hudson Bay Capital Management LP | 350.0K | $1.6M | -325.0K (-48.1%) | Trimmed |
| 16 | Swiss National Bank | 283.4K | $1.3M | +0 (+0.0%) | No change |
| 17 | Ledgewood Wealth Advisors, LLC | 278.4K | $1.3M | +0 (+0.0%) | No change |
| 18 | Nuveen, LLC | 259.0K | $1.2M | +1.1K (+0.4%) | Added |
| 19 | Carrera Capital Advisors | 252.2K | $1.1M | — | New |
| 20 | Invesco Ltd. | 247.9K | $1.1M | +671 (+0.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ABUS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.